Arvin Dar is a member and professor in the Chemical Biology Program at Memorial Sloan Kettering Cancer Center’s Sloan Kettering Institute, where he is also vice director of the Center for Experimental Therapeutics. Dr. Dar graduated from the University of Western Ontario with a BSc in chemistry, completed his PhD at the University of Toronto, and received postdoctoral training at the University of California, San Francisco. Prior to joining MSK in June of 2023, Dr. Dar led an independent research group at Mount Sinai, NYC for approximately 10 years. Dr. Dar has expertise in small molecule design and synthesis, as well as in structural biology. His laboratory develops chemical tools and approaches to investigate signal transduction and cancer, with specific applications in the areas of drug mechanisms, target discovery, and the development of probes for cellular and in vivo studies. The group is particularly interested in developing small molecule modulators and molecular glues against kinases, GTPases, and scaffolding proteins. In addition, Dr. Dar co-founded Nested Therapeutics and Prometeo Therapeutics to advance new therapeutic approaches aimed at challenging disease targets. Dr. Dar is a Fellow of the National Academy of Inventors (NAI) and has received numerous awards and honors for his research, including the NIH Director’s New Innovator Award, Damon Runyon-Rachleff Innovation Award, the Pew Charitable Trusts’ Pew-Stewart Scholars for Cancer Research award, the Pershing Square Sohn Cancer Research Alliance Award, and the Mark Foundation for Cancer Research ASPIRE Award.